Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes
Open accessThe DOI matches its Crossref record; 44 of the 45 references it cites were found in a registry or an index.
Abstract
AIMS/HYPOTHESIS: Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was 'isolated' through comparison to diet, lifestyle or placebo. METHODS: We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. RESULTS: We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel-Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). CONCLUSIONS/INTERPRETATION: There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram [40]](https://figures.cochat.ai/paper-figures/21d83ef63bbb4a5890ce9f40e21450f3/impact-of-metformin-on-cardiovascular-disease-a-meta-analysis-of-randomised-figure-1.jpg)







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In meta-analyses of 13 randomized clinical trials evaluating the CV effects of metformin vs. placebo or active control, including the data from the UKPDS, none of the differences in assessed CV outcomes was statistically significant.184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Excepting glimepiride, which was assessed for CV safety and efficacy head-to-head against linagliptin in the CAROLINA trial, and gliclazidemodified release, which was compared with usual care (that could have included treatment with a sulphonylurea other than gliclazide) in the ADVANCE trial, dedicated CV safety assessments have not been conducted for the other sulphonylureas.132,173,174,184”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“12 weeks of treatment with licogliflozin led to a numerically greater reduction in liver lipid content, body weight (4.2 %) and HbA1c (1 %) compared to RCTs with sole SGLT2I treatment (Table 1) [161,163].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [163]
Experimental — accuracy not yet measuredIn the citing paper
“This Class IIa recommendation for metformin is based on the weight of opinion rather than the weight of evidence; results from meta-analyses of observational studies suggest associations with better CV outcome, but this is not supported by results from meta-analyses restricted to randomized trials in patients with T2DM and ASCVD, where no statistically significant effect of metformin has been”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
In the citing paper
“The pooled HRs (95% CIs) were: all-cause mortality 0.96 (0.84-1.09);CV death 0.97 ( 0.80-1.16); MI 0.89 (0.75-1.06); stroke 1.04 (0.73-1.48); and peripheral vascular disease 0.81 (0.50-1 31).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [184]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Metformin monotherapy for type 2 diabetes mellitus
Saenz, A., Fernandez-Esteban, I., Mataix, A., Ausejo Segura, M., Roqué i Figuls, M., & Moher, D. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002966.pub3 · Cited by 308
RetractedPreferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Metformin reduced the incidence of diabetes by 31% among people with glucose levels just below the diagnostic threshold in the US Diabetes Prevention Programme [36], and by 26% in the Indian equivalent [37].”
BackgroundEmpagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 10×
“studies [19, 21] to 15 years [27]) and poorly controlled diabetes (average baseline HbA1c was less than 8% [63.”
BackgroundMethodInfluentialLiraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“This contrasts with the evidence now available for newer and more expensive glucose-lowering drugs, such as empagliflozin [34] and liraglutide [10], and of course for medications targeting different risk factors, for example statins.”
Background
Cited by
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Circulation · doi:10.1161/cir.0000000000000678 · Cited by 4,536
(2019) · doi:10.1161/cir.0000000000000677 · Cited by 4,501
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518
The mechanisms of action of metformin
Rena, G., Hardie, D. G., & Pearson, E. R. (2017) · Diabetologia · doi:10.1007/s00125-017-4342-z · Cited by 2,287
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.010 · Cited by 1,896
2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes.
Marx, N., Federici, M., Schütt, K., Müller-Wieland, D., Ajjan, R. A., Antunes, M. J., Christodorescu, R. M., Crawford, C., Di Angelantonio, E., Eliasson, B., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad192 · Cited by 1,642
Chait, A., & den Hartigh, L. J. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00022 · Cited by 1,529
“A recent meta-analysis suggested that metformin could contribute to a 16% decrease in all-cause mortality, but may also contribute to a 48% increased risk of stroke (570).”
BackgroundDavies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetologia · doi:10.1007/s00125-018-4729-5 · Cited by 1,455
2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary
Arnett, D. K., Blumenthal, R. S., Albert, M. A., Buroker, A. B., Goldberger, Z. D., Hahn, E. J., Himmelfarb, C. D., Khera, A., Lloyd-Jones, D., McEvoy, J. W., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.009 · Cited by 1,193
Targher, G., Byrne, C. D., & Tilg, H. (2020) · Gut · doi:10.1136/gutjnl-2020-320622 · Cited by 827
Metformin: clinical use in type 2 diabetes
Sanchez-Rangel, E., & Inzucchi, S. E. (2017) · Diabetologia · doi:10.1007/s00125-017-4336-x · Cited by 595
“Interestingly, and despite this popularity, there still remains controversy about the drug’s precise mechanism of action, although most data point to a reduction in hepatic glucose production being predominately involved (described further by Rena et al in this issue of Diabetologia) [4]; although, recent data suggest…”
BackgroundInfluentialInsulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Di Pino, A., & DeFronzo, R. A. (2019) · Endocrine Reviews · doi:10.1210/er.2018-00141 · Cited by 535
From pre-diabetes to diabetes: diagnosis, treatments and translational research
Khan, R., Chua, Z., Tan, J., Yang, Y., Liao, Z., & Zhao, Y. (2019) · Medicina · doi:10.3390/medicina55090546 · Cited by 484
“In humans, the main site of action of Metformin is the intestines, liver and kidney [162,163].”
BackgroundPapachristoforou, E., Lambadiari, V., Maratou, E., & Makrilakis, K. (2020) · Journal of Diabetes Research · doi:10.1155/2020/7489795 · Cited by 479
“Emerging evidence suggests that metformin boasts both direct and indirect antioxidant and anti-inflammatory properties, which may be contributing to its CVD protective effects [107].”
BackgroundFlory, J., & Lipska, K. (2019) · JAMA · doi:10.1001/jama.2019.3805 · Cited by 453
Han, Y., Xie, H., Liu, Y., Gao, P., Yang, X., & Shen, Z. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0900-7 · Cited by 337
Mohammed, I., Hollenberg, M. D., Ding, H., & Triggle, C. R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.718942 · Cited by 278
Metformin: Is it a drug for all reasons and diseases?
Triggle, C. R., Mohammed, I., Bshesh, K., Marei, I., Ye, K., Ding, H., MacDonald, R., Hollenberg, M. D., & Hill, M. A. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155223 · Cited by 275
Metformin: An Old Drug with New Applications
Zhou, J., Massey, S., Story, D., & Li, L. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102863 · Cited by 233
Kulkarni, A. S., Brutsaert, E. F., Anghel, V., Zhang, K., Bloomgarden, N., Pollak, M., Mar, J. C., Hawkins, M., Crandall, J. P., & Barzilai, N. (2018) · Aging Cell · doi:10.1111/acel.12723 · Cited by 183
Should metformin remain the first-line therapy for treatment of type 2 diabetes?
Baker, C., Retzik-Stahr, C., Singh, V., Plomondon, R., Anderson, V., & Rasouli, N. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018820980225 · Cited by 181
Goldberg, R. B., Orchard, T. J., Crandall, J. P., Boyko, E. J., Budoff, M., Dabelea, D., Gadde, K. M., Knowler, W. C., Lee, C. G., Nathan, D. M., et al. (2022) · Circulation · doi:10.1161/circulationaha.121.056756 · Cited by 173
Mohan, M., Al-Talabany, S., McKinnie, A., Mordi, I. R., Singh, J. S. S., Gandy, S. J., Baig, F., Hussain, M. S., Bhalraam, U., Khan, F., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz203 · Cited by 170
“.. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..been a small number of RCTs.28 While patients with cardiovascular disease (CVD) with T2DM comorbidity are likely to benefit most from metformin, indications of CV benefit over other dia…”
BackgroundStimulation of AMPK prevents degeneration of photoreceptors and the retinal pigment epithelium
Xu, L., Kong, L., Wang, J., & Ash, J. D. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802724115 · Cited by 160
Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease?
Huttasch, M., Roden, M., & Kahl, S. (2024) · Metabolism · doi:10.1016/j.metabol.2024.155937 · Cited by 169
The Current and Potential Therapeutic Use of Metformin—The Good Old Drug
Drzewoski, J., & Hanefeld, M. (2021) · Pharmaceuticals · doi:10.3390/ph14020122 · Cited by 195
“The emerging doubts will be difficult to dispel because conducting a large, long-term study assessing the effect of metformin monotherapy on the cardiovascular system is, for many reasons, extremely difficult to implement [9].”
BackgroundCardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis
Fei, Y., Tsoi, M.-F., & Cheung, B. M. Y. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0916-z · Cited by 156
Glossmann, H. H., & Lutz, O. M. D. (2019) · Gerontology · doi:10.1159/000502257 · Cited by 149
Repurposing Metformin for Cardiovascular Disease
Rena, G., & Lang, C. C. (2018) · Circulation · doi:10.1161/circulationaha.117.031735 · Cited by 155
“Future prospects The present clinical equipoise for metformin in CVD without T2D has led to a call for CV endpoint trials of metformin in the absence of diabetes (1) and it is timely to consider how”
Bjornstad, P., Schäfer, M., Truong, U., Cree-Green, M., Pyle, L., Baumgartner, A., Garcia Reyes, Y., Maniatis, A., Nayak, S., Wadwa, R. P., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.035525 · Cited by 143
Wang, G., Wang, Y., Yang, Q., Xu, C., Zheng, Y., Wang, L., Wu, J., Zeng, M., & Luo, M. (2022) · Cell Death and Disease · doi:10.1038/s41419-021-04478-x · Cited by 158
60 years of metformin use: a glance at the past and a look to the future
Marshall, S. M. (2017) · Diabetologia · doi:10.1007/s00125-017-4343-y · Cited by 150
Sanches-Silva, A., Testai, L., Nabavi, S. F., Battino, M., Pandima Devi, K., Tejada, S., Sureda, A., Xu, S., Yousefi, B., Majidinia, M., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104626 · Cited by 135
Mitochondria-Associated Endoplasmic Reticulum Membranes in Cardiovascular Diseases
Gao, P., Yan, Z., & Zhu, Z. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.604240 · Cited by 141
Zhao, W., & Sheng, R. (2024) · Acta Pharmacologica Sinica · doi:10.1038/s41401-024-01359-9 · Cited by 144
“This effect is achieved by activating AMPK, which in turn helps to alleviate Ca 2 + overload in cardiomyocyte mitochondria [69].”
Feng, X., Pan, J., Li, J., Zeng, C., Qi, W., Shao, Y. X., Liu, X., Liu, L., Xiao, G., Zhang, H., et al. (2020) · Aging · doi:10.18632/aging.102635 · Cited by 128
Metformin: Therapeutic profile in the treatment of type 2 diabetes
Bailey, C. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15663 · Cited by 175
“123 Although metformin can reduce long-term CV adverse events, it is reiterated that hypoxaemic conditions such as acute severe myocardial ischaemia are contraindications for metformin, and metformin should be discontinued during such episodes.”
Sibony, R. W., Segev, O., Dor, S., & Raz, I. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms242417147 · Cited by 167
“However, no effect reached statistical significance, mainly due to the absence of high-quality evidence [18].”
BackgroundThe pharmacological management of metabolic syndrome
Rask Larsen, J., Dima, L., Correll, C. U., & Manu, P. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1429910 · Cited by 113
“CVD results, when treating with metformin [120].”
Metformin as a geroprotector: experimental and clinical evidence
Piskovatska, V., Stefanyshyn, N., Storey, K. B., Vaiserman, A. M., & Lushchak, O. V. (2018) · Biogerontology · doi:10.1007/s10522-018-9773-5 · Cited by 115
“In response to energy stress, AMPK suppresses biosynthetic processes and cellular growth, in part via inhibiting the mTORC1 pathway (Gwinn et al. 2008; Hindupur et al. 2015).”
Chinese Guideline on the Primary Prevention of Cardiovascular Diseases
Chinese Society of Cardiology of Chinese Medical Association, C. D. P. A. R. C. O. C. A. O. R. M. (2021) · Cardiology Discovery · doi:10.1097/cd9.0000000000000025 · Cited by 133
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
Kalyani, R. R. (2021) · New England Journal of Medicine · doi:10.1056/nejmcp2000280 · Cited by 101
Li, T., Providencia, R. A., Mu, N., Yin, Y., Chen, M., Wang, Y., Liu, M., Yu, L., Gu, C., & Ma, H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-020-01202-5 · Cited by 106
“Thirdly, we did not include cohort studies, where most showed positive benefits for metformin, in fear of introducing selection bias [14, 58].”
BackgroundResultInfluentialHerrington, W. G., Judge, P. K., Grams, M. E., & Wanner, C. (2025) · The Lancet · doi:10.1016/s0140-6736(25)01942-7 · Cited by 150
Can Metformin Exert as an Active Drug on Endothelial Dysfunction in Diabetic Subjects
Salvatore, T., Pafundi, P. C., Galiero, R., Rinaldi, L., Caturano, A., Vetrano, E., Aprea, C., Albanese, G., Di Martino, A., Ricozzi, C., et al. (2020) · Biomedicines · doi:10.3390/biomedicines9010003 · Cited by 97
“Another metanalysis of randomized trials has left doubts about whether metformin reduces risk of cardiovascular disease in T2DM or not [124].”
BackgroundEffects of Metformin in Heart Failure: From Pathophysiological Rationale to Clinical Evidence
Salvatore, T., Galiero, R., Caturano, A., Vetrano, E., Rinaldi, L., Coviello, F., Martino, A. D., Albanese, G., Marfella, R., Sardu, C., et al. (2021) · Biomolecules · doi:10.3390/biom11121834 · Cited by 102
Cardiorenal diseases in type 2 diabetes mellitus: clinical trials and real-world practice
Lim, L.-L., Chow, E., & Chan, J. C. N. (2023) · Nature Reviews Endocrinology · doi:10.1038/s41574-022-00776-2 · Cited by 91
Coagulatory Defects in Type-1 and Type-2 Diabetes
Sobczak, A. I. S., & Stewart, A. J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20246345 · Cited by 107
“Two meta-analyses have shown that when metformin is used alone, it does not have a significant effect on cardiovascular disease risk in T2DM; however, these analyses mostly included short-term studies [196,197], while another meta-analysis and a study that followed patients over a longer period (the UK Prospective Dia…”
ResultMechanisms of action of metformin with special reference to cardiovascular protection
Zilov, A. V., Abdelaziz, S. I., Alshammary, A., Zahrani, A. A., Amir, A., Khalil, S. H. A., Brand, K. M. G., Elkafrawy, N., Hassoun, A. A. K., Jahed, S. A., et al. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3173 · Cited by 94
Vilar‐Gomez, E., Vuppalanchi, R., Desai, A. P., Gawrieh, S., Ghabril, M., Saxena, R., Cummings, O. W., & Chalasani, N. (2019) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.15331 · Cited by 84
Mechanism of glucose-lowering by metformin in type 2 diabetes: Role of bile acids
Sansome, D. J., Xie, C., Veedfald, S., Horowitz, M., Rayner, C. K., & Wu, T. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13869 · Cited by 84
Chunxing, L., Liang, S., Gao, L., & Liu, H. (2021) · PLoS ONE · doi:10.1371/journal.pone.0244689 · Cited by 86
“Metformin [4, 5] and glucagon-like peptide 1 receptor agonists (GLP-1RA) are known to have cardiovascular protective effects [6–9].”
BackgroundDiabetes and its complications: molecular mechanisms, prevention and treatment
Zhao, L., Yuan, J., Yang, Q., Ma, J., Yang, F., Zou, Y., Liu, K., & Liu, F. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02401-w · Cited by 80
“269,270 Its utility is limited in patients with advanced CKD owing to safety concerns.”
Neuen, B. L., Arnott, C., Perkovic, V., Figtree, G., de Zeeuw, D., Fulcher, G., Jun, M., Jardine, M. J., Zoungas, S., Pollock, C., et al. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14226 · Cited by 78
Antiaging effects of bioactive molecules isolated from plants and fungi
Martel, J., Ojcius, D. M., Ko, Y., Chang, C., & Young, J. D. (2019) · Medicinal Research Reviews · doi:10.1002/med.21559 · Cited by 81
“Metformin is also associated with a reduced incidence of cancer(140) and cardiovascular disease.(141) Autophagy is required for the life extension effects of resveratrol and CR in worms, fruit flies, and mice.”
BackgroundInsulin Resistance the Link between T2DM and CVD: Basic Mechanisms and Clinical Implications
Abdul‐Ghani, M. A., Jayyousi, A., DeFronzo, R. A., Asaad, N., & Suwaidi, J. M. S. A. (2017) · Current Vascular Pharmacology · doi:10.2174/1570161115666171010115119 · Cited by 82
Zhang, K., Yang, W., Dai, H., & Deng, Z. (2020) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2020.108001 · Cited by 86
Cardiovascular outcomes trials: a paradigm shift in the current management of type 2 diabetes
Davies, M. J., Drexel, H., Jornayvaz, F. R., Pataky, Z., Seferovic, P. M., & Wanner, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01575-9 · Cited by 83
Metformin selectively dampens the acute inflammatory response through an AMPK-dependent mechanism
Postler, T. S., Peng, V., Bhatt, D. M., & Ghosh, S. (2021) · Scientific Reports · doi:10.1038/s41598-021-97441-x · Cited by 75
Chan, M. S., Arnold, M., Offer, A. R., Hammami, I., Mafham, M. M., Armitage, J., Perera, R., & Parish, S. (2021) · The Journals of Gerontology Series A · doi:10.1093/gerona/glab069 · Cited by 79
Sattar, N., Presslie, C., Rutter, M. K., & McGuire, D. K. (2024) · Diabetes Care · doi:10.2337/dci23-0041 · Cited by 70
Schernthaner, G., Brand, K. M. G., & Bailey, C. J. (2022) · Metabolism · doi:10.1016/j.metabol.2022.155160 · Cited by 77
Bashier, A. M., Hussain, A. K. B., Abdelgadir, E., Alawadi, F., Sabbour, H. M., & CHILTON, R. J. (2019) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-019-0476-0 · Cited by 67
Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62
Metformin in Patients With COVID-19: A Systematic Review and Meta-Analysis
Li, Y., Yang, X., Yan, P., Sun, T., Zeng, Z., & Li, S. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.704666 · Cited by 67
Blood Sugar Regulation for Cardiovascular Health Promotion and Disease Prevention
Schwarz, P. E. H., Timpel, P., Harst, L., Greaves, C. J., Ali, M. K., Lambert, J., Weber, M. B., Almedawar, M. M., & Morawietz, H. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.07.081 · Cited by 60
Health Benefits of Anti-aging Drugs
Piskovatska, V., Strilbytska, O. M., Koliada, A. K., Vaiserman, A. M., & Lushchak, O. V. (2019) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/978-981-13-3681-2_13 · Cited by 64
Efficacy and Safety of Metformin Use in Rheumatoid Arthritis: A Randomized Controlled Study
Gharib, M., El-Baz, W., Darweesh, E. A. G., Sabri, N. A., & Shawki, M. A. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.726490 · Cited by 60
“It is worthy to mention that metformin might have additional benefits in RA patients due to its possession of positive effects on cardiac outcomes, including reduced cardiac ischemia, myocardial infarction, cardiovascular death, and all-cause mortality in patients with type II diabetes (Griffin et al., 2017).”
BackgroundMetformin, lipids and atherosclerosis prevention
Jenkins, A. J., Welsh, P., & Petrie, J. R. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000532 · Cited by 55
Mo, D., Liu, S., Ma, H., Tian, H., Yu, H., Zhang, X., Tong, N., Liao, J., & Ren, Y. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s208327 · Cited by 58
“However, the effect of metformin on vascular complications remains uncertain.(12,13) Acarbose, an α-glycosidase inhibitor, is commonly used to treat Chinese patients with diabetes.”
BackgroundYeung, S. L. A., Luo, S., & Schooling, C. M. (2019) · Diabetologia · doi:10.1007/s00125-019-4913-2 · Cited by 61
Updates on cardiovascular outcome trials in diabetes
on behalf of the D&CVD EASD Study Group, Schnell, O., Rydén, L., Standl, E., & Ceriello, A. (2017) · Cardiovascular Diabetology · doi:10.1186/s12933-017-0610-y · Cited by 52
“A meta-analysis concluded, that a CV risk of metformin in T2DM patients could not be determined mainly due to the low amount of information currently available [39].”
BackgroundRepurposing Antidiabetic Drugs for Cardiovascular Disease
Schubert, M., Hansen, S., Leefmann, J., & Guan, K. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.568632 · Cited by 61
“In addition, some meta-analyses could not confirm the cardioprotective effect of metformin in T2D patients, although including data from the UKPDS34 trial (Griffin et al., 2017; Harrington et al., 2018).”
ResultRecommendations for Practical Use of Metformin, a Central Pharmacological Therapy in Type 2 Diabetes
Vieira, I. H., Barros, L. M., Baptista, C. F., Rodrigues, D. M., & Paiva, I. (2021) · Clinical Diabetes · doi:10.2337/cd21-0043 · Cited by 64
Patient and physician preferences for type 2 diabetes medications: a systematic review
Toroski, M., Kebriaeezadeh, A., Esteghamati, A., Karyani, A. K., Abbasian, H., & Nikfar, S. (2019) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-019-00449-4 · Cited by 52
“Therefore, reducing cardiovascular risk using anti-diabetic medicines is considerable for patients and physicians [36, 45].”
BackgroundUnosson, J., Wågsäter, D., Bjarnegård, N., Basso, R. D., Welander, M., Mani, K., Gottsäter, A., & Wanhainen, A. (2020) · Annals of Vascular Surgery · doi:10.1016/j.avsg.2020.06.039 · Cited by 55
“16 Metformin has been proposed to reduce AAA growth by inhibiting key pathologic mechanisms implicated in AAA, including inflammation and extracellular matrix remodeling.”
(2020) · International Review of Neurobiology · doi:10.1016/bs.irn.2020.03.018 · Cited by 50
Where Does Metformin Stand in Modern Day Management of Type 2 Diabetes?
Ahmad, E., Sargeant, J. A., Zaccardi, F., Khunti, K., Webb, D. R., & Davies, M. J. (2020) · Pharmaceuticals · doi:10.3390/ph13120427 · Cited by 59
“It was acknowledged that a lot of this uncertainty was due to lack of a large randomised double-blind, placebo controlled trial with dedicated MACE end-points [45], lack of long-term evaluations [26] and the unexplained deleterious effect of the combination of metformin plus SU from the UKPDS data [25,46].”
BackgroundEvaluation and management of extrahepatic manifestations of nonalcoholic fatty liver disease
Wijarnpreecha, K., Aby, E. S., Ahmed, A., & Kim, D. (2020) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2020.0239 · Cited by 59
“(1, 20, 46, 47) Recent studies reported that metformin use was associated with lower CVD and CVD-related mortality in patients with and without diabetes.(48, 49) However, metformin has not been shown to improve NASH or liver fibrosis.”
BackgroundSeidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2022) · Primary Care Diabetes · doi:10.1016/j.pcd.2022.02.002 · Cited by 48
Krishnan, A., Schneider, C. V., Hadi, Y. B., Mukherjee, D., Alshehri, B. Y., & Alqahtani, S. A. (2023) · Diabetologia · doi:10.1007/s00125-023-06057-5 · Cited by 57
“The cardioprotective effect of metformin in patients with type 2 diabetes is not only attributable to its glucose-lowering effects but also to its significant antihypertensive properties [33].”
Top, W. M. C., Kooy, A., & Stehouwer, C. D. A. (2022) · Pharmaceuticals · doi:10.3390/ph15030312 · Cited by 54
“Griffin 2017 [59] 13 Diet, lifestyle, placebo All-cause mortality 0.”
Metformin and cardiorenal outcomes in diabetes: A reappraisal
Petrie, J. R., Rossing, P. R., & Campbell, I. W. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13984 · Cited by 49
“24 A recent, very large meta-analysis included more than 1 million patients, who participated in 40 randomized or observational evaluations of metformin.”
Dludla, P. V., Nyambuya, T. M., Johnson, R., Silvestri, S., Orlando, P., Mazibuko-Mbeje, S. E., Gabuza, K., Mxinwa, V., Mokgalaboni, K., Tiano, L., et al. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09942-y · Cited by 51
Karlstaedt, A., Barrett, M., Hu, R., Gammon, S. T., & Ky, B. (2021) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2021.05.008 · Cited by 51
“These effects increase reliance on glycolysis for ATP provision and make cancer cells more vulnerable to limited glucose availability, thus highlighting the anticancer properties of metformin, particularly in tumors with high levels of organic cation transporters (106,107).”
BackgroundLi, T., Providencia, R. A., Jiang, W., Mu, N., Wang, Y., Li, X., Yin, Y., Liu, M., Yu, L., Gu, C., et al. (2022) · Drugs · doi:10.1007/s40265-021-01665-0 · Cited by 50
“are studies that doubt the protective effects of metformin [72, 73], but based on multiple RCTs and cohort studies that take into account multiple possible factors, we demonstrate the benefits of metformin in reducing mortality and CVD.”
BackgroundOverview of Metformin and Neurodegeneration: A Comprehensive Review
Kruczkowska, W., Gałęziewska, J., Buczek, P., Płuciennik, E., Kciuk, M., & Śliwińska, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040486 · Cited by 58
Damanhouri, Z. A., Alkreathy, H. M., Alharbi, F. A., Abualhamail, H., & Ahmad, M. S. (2023) · International Journal of Medical Sciences · doi:10.7150/ijms.77206 · Cited by 58
“In the skeletal muscle cells, metformin activates AMPK to promote glucose uptake by increasing SLC2A4 encoded glucose transporter type 4 (GLUT-4) translocation (46, 47).”
Seidu, S., Cos, X., Brunton, S., Harris, S. B., Jansson, S. P. O., Mata-Cases, M., Neijens, A. M. J., Topsever, P., & Khunti, K. (2021) · Primary Care Diabetes · doi:10.1016/j.pcd.2020.05.004 · Cited by 45
Greiver, M., Havard, A., Bowles, J., Kalia, S., Chen, T., Aliarzadeh, B., Moineddin, R., Sherlock, J., Hinton, W., Sullivan, F., et al. (2020) · British Journal of General Practice · doi:10.3399/bjgp20x714089 · Cited by 46
“21 It is possible that SGLT2s and GLP1s may be preferred as first line in the future, 22 though this is not yet recommended in guidelines.”
Cosentino, F., Ceriello, A., Baeres, F. M. M., Fioretto, P., Garber, A., Stough, W. G., George, J. T., Grant, P. J., Khunti, K., Langkilde, A. M., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehy677 · Cited by 44
Bromage, D. I., Godec, T. R., Pujades‐Rodríguez, M., González-Izquierdo, A., Denaxas, S., Hemingway, H., & Yellon, D. M. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0972-4 · Cited by 46
Shoshan‐Barmatz, V., Anand, U., Crystal, E. N., Carlo, M. D., & Shteinfer‐Kuzmine, A. (2021) · Frontiers in Physiology · doi:10.3389/fphys.2021.730048 · Cited by 44
Association of metformin use with vitamin B12 deficiency in the institutionalized elderly
Wong, C. W., Leung, C. S., Leung, C. P., & Cheng, J. N. (2018) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2018.07.019 · Cited by 48
Cellular mechanisms and recommended drug-based therapeutic options in diabetic cardiomyopathy
Dannenberg, L., Weske, S., Kelm, M., Levkau, B., & Polzin, A. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107920 · Cited by 43
GDF-15 as a Weight Watcher for Diabetic and Non-Diabetic People Treated With Metformin
Ouyang, J., Isnard, S., Lin, J., Fombuena, B., Peng, X., Chen, Y., & Routy, J.-P. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.581839 · Cited by 39
“Metformin is also suggested to prevent cardiovascular diseases and to have anti-aging effects (15, 92–94), although these results need to be confirmed (95).”
BackgroundTargeting β-cell dedifferentiation and transdifferentiation: opportunities and challenges
Wang, W., & Zhang, C. (2021) · Endocrine Connections · doi:10.1530/ec-21-0260 · Cited by 43
Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Masson, W., Lavalle-Cobo, A., Lobo, M., Masson, G., & Molinero, G. (2021) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwaa074 · Cited by 37
Mbara, K. C., Mato, P. E. M., Driver, C., Nzuza, S., Mkhombo, N. T., Gcwensa, S. K., Mcobothi, E. N., & Owira, P. M. O. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.173934 · Cited by 36
Metadata
- Authors
- Griffin, S. J., Leaver, J. K., & Irving, G. J.
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- Griffin, Simon J.
- Venue
- Diabetologia
- Published
- 2017-08-02
- Volume
- 60
- Issue
- 9
- Pages
- 1620-1629
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC5552849
- OpenAlex
- W2740802742
- Cited by
- 398
- References
- 45
- Citations by year
- 2026: 13 · 2025: 23 · 2024: 33 · 2023: 31 · 2022: 52 · 2021: 60 · 2020: 75 · 2019: 64 · 2018: 39 · 2017: 8
- FWCI
- 7.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Diabetologia (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Edge Hill University Research Information Repository (Edge Hill University) (publishedVersion, cc-by)
- Apollo (University of Cambridge) (submittedVersion, cc-by)
- Apollo (cc-by)
- Funders
- University of Cambridge
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- metformin, type 2 diabetes, cardiovascular disease, myocardial infarction, stroke, all-cause mortality, cardiovascular mortality, peripheral vascular disease, ischemic heart disease, UK Prospective Diabetes Study, lifestyle intervention, drug effectiveness, cardiovascular risk reduction, glycemic control, randomized controlled trials, meta-analysis of trials, study heterogeneity, publication bias
- MeSH terms
- Blood Glucose, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.